Molecular discrimination of cutaneous squamous cell carcinoma from actinic keratosis and normal skin

Modern Pathology

Volumn 24, Issue 7, 2011, Pages 963-973

  Ra, Seong Hui ^a   Li, Xinmin ^a   Binder, Scott ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

actinic keratosis; differential gene expression; formalin fixed and paraffin embedded tissue; microarray; squamous cell carcinoma

Indexed keywords

DNA; RNA;

ACTINIC KERATOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION; GENE IDENTIFICATION; MOLECULAR DIAGNOSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA HYBRIDIZATION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; UNINDEXED SEQUENCE;

EID: 79959971790     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.39     Document Type: Article

References (72)

1. Alam M, Ratner D. Cutaneous squamous cell carcinoma. N Eng J Med 2001;344:975-983.
2. Smoller BR. Squamous cell carcinoma: from precursor lesions to high-risk variants. Mod Pathol 2006;19 (Suppl 2):S88-S92. (Pubitemid 43172311)
3. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006;155:9-22. (Pubitemid 43876387)
4. Lober BA, Lober CW. Actinic keratosis is squamous cell carcinoma. South Med J 2000;93:650-655.
5. Dooley TP, Reddy SP, Wilborn TW, et al. Biomarkers of human cutaneous squamous cell carcinoma from tissues and cell lines identified by DNA microarrays and qRT-PCR. Biochem Biophys Res Commun 2003;11:1026-1036. (Pubitemid 36776234)
6. Kathpalia VP, Mussactinic keratosis EN, Chow SS, et al. Genome-wide transcriptional profiling in human squamous cell carcinoma of the skin identifies unique tumorassociated signatures. J Dermatol 2006;33:309-318. (Pubitemid 43943363)
7. Nindl I, Dang C, Forschner T, et al. Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer 2006;5:30.
8. Haider AS, Peters SB, Kaporis H, et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol 2006;126:869-881.
9. Serewko MM, Popa C, Dahler AL, et al. Alterations in gene expression and activity during squamous cell carcinoma development. Cancer Res 2002;62:3759-3765. (Pubitemid 34728858)
10. Czarnecki D, Meehan CJ, Bruce F, et al. The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg 2002;6:207-209. (Pubitemid 34839927)
11. Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21stcentury perspective. Arch Dermatol 2003;139:66-70. (Pubitemid 36091577)
12. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. J Cutan Pathol 2006;33:191-206.
13. Ramachandran S, Liu P, Young AN, et al. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005;24:188-198. (Pubitemid 40143878)
14. McCabe CD, Spyropoulos DD, Martin D, et al. Genomewide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res 2008;68:1988-1996. (Pubitemid 351416586)
15. Legg JA, Herbert JM, Clissold P, et al. Slits and roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis 2008;11:13-21.
16. Gröne J, Doebler O, Loddenkemper C, et al. Robo1/ Robo4: differential expression of angiogenic markers in colorectal cancer. Oncol Rep 2006;15:1437-1443.
17. Liu Z, Yang X, Tan F, et al. Molecular cloning and characterization of human Castor, a novel human gene upregulated during cell differentiation. Biochem Biophys Res Commun 2006;344:834-844.
18. Kuhlmann T, Gutenberg A, Schulten HJ, et al. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas? Am J Surg Pathol 2008;32:1444-1453.
19. Xiong NX, Zhao HY, Zhang FC, et al. Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor. Neurosci Bull 2007;23:41-45.
20. Pierron A, Fernandez C, Saada E, et al. HMGA2-NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor. Cancer Genet Cytogenet 2009;195:66-70.
21. Nilsson M, Panagopoulos I, Mertens F, et al. Fusion of the HMGA2 and NFIB genes in lipoma. Virchows Arch 2005;447:855-858. (Pubitemid 41728875)
22. Marchiò C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). J Clin Pathol 2010;63:220-228.
23. Kikuchi A, Yamamoto H. Tumor formation due to abnormalities in the beta-catenin-independent pathway of Wnt signaling. Cancer Sci 2008;99:202-208. (Pubitemid 351228471)
24. Miller JR, Hocking AM, Brown JD, et al. Mechanism and function of signal transduction by the Wnt/betacatenin and Wnt/Ca2+ pathways. Oncogene 1999;18:7860-7872. (Pubitemid 30066232)
25. Jin T, George Fantus I, Sun J. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal 2008;20:1697-1704.
26. Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma 2008;55:165-176.
27. Capiod T, Shuba Y, Skryma R, et al. Calcium signalling and cancer cell growth. Subcell Biochem 2007;45: 405-427.
28. Whitfield JF. Calcium, calcium-sensing receptor and colon cancer. Cancer Lett 2009;275:9-16.
29. Sergeev IN. Calcium signaling in cancer and vitamin D. J Steroid Biochem Mol Biol 2005;97:145-151. (Pubitemid 41546224)
30. Taylor JT, Zeng XB, Pottle JE, et al. Calcium signaling and T-type calcium channels in cancer cell cycling. World J Gastroenterol 2008;14:4984-4991.
31. Panner A, Wurster RD. T-type calcium channels and tumor proliferation. Cell Calcium 2006;40:253-259. (Pubitemid 43942305)
32. Rodland KD. The role of the calcium-sensing receptor in cancer. Cell Calcium 2004;35:291-295. (Pubitemid 38292373)
33. Chactinic keratosisravarti B, Dwivedi SK, Mithal A, et al. Calcium-sensing receptor in cancer: good cop or bad cop? Endocrine 2009;35:271-284.
34. Bikle DD, Oda Y, Xie Z. Calcium and 1,25(OH)2D: interacting drivers of epidermal differentiation. J Steroid Biochem Mol Biol 2004;89-90:355-360. (Pubitemid 38844310)
35. Bikle DD. Vitamin D regulated keratinocyte differentiation. J Cell Biochem 2004;92:436-444.
36. Lu F, Chen H, Zhou C, et al. T-type Ca2+ channel expression in human esophageal carcinomas: a functional role in proliferation. Cell Calcium 2008;43: 49-58.
37. Li Y, Liu S, Lu F, et al. A role of functional T-type Ca2+ channel in hepatocellular carcinoma cell proliferation. Oncol Rep 2009;22:1229-1235.
38. Moschos SJ, Drogowski LM, Reppert SL, et al. Integrins and cancer. Oncology (Williston Park) 2007;21(9 Suppl 3):13-20.
39. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
40. Friedrichs K, Ruiz P, Franke F, et al. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 1995;55:901-906.
41. Hazelbag S, Kenter GG, Gorter A, et al. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 2007;212:316-324. (Pubitemid 47010065)
42. Bates RC, Bellovin DI, Brown C, et al. Transcriptional activation of integrin beta6 during the epithelialmesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005;115:339-347. (Pubitemid 40385475)
43. Hieken TJ, Ronan SG, Farolan M, et al. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 1999;85:375-382. (Pubitemid 29051292)
44. Sloan EK, Pouliot N, Stanley KL, et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 2006;8:R20.
45. McCabe NP, De S, Vasanji A, et al. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007;26:6238-6243. (Pubitemid 47414368)
46. Hosotani R, Kawaguchi M, Masui T, et al. Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas 2002;25:e30-e35.
47. Morozevich G, Kozlova N, Cheglactinic keratosisov I, et al. Integrin alpha5beta1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity. Cell Cycle 2008;15:2219-2225.
48. MacDonald TJ, Stewart CF, Kocactinic keratosis M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008;26:919-924. (Pubitemid 351398085)
49. Le Tourneau C, Faivre S, Raymond E. The role of integrins in colorectal cancer. Oncology (Williston Park) 2007;21(9 Suppl 3):21-24.
50. Orimoto AM, Neto CF, Pimentel ER, et al. High numbers of human skin cancers express MMP2 and several integrin genes. J Cutan Pathol 2008;35:285-291. (Pubitemid 351171255)
51. Janes SM,Watt FM. New roles for integrins in squamouscell carcinoma. Nat Rev Cancer 2006;6:175-183. (Pubitemid 43292561)
52. Brash DE, Ziegler A, Jonason AS, et al. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc 1996;1:136-142. (Pubitemid 126759356)
53. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994;85:23-29. (Pubitemid 24280158)
54. Benjamin CL, Melnikova VO, Ananthaswamy HN. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008;624:265-282.
55. Tactinic keratosisata M, Saida T. Early cancers of the skin: clinical, histopathological, and molecular characteristics. Int J Clin Oncol 2005;10:391-397. (Pubitemid 41821522)
56. Al Moustafa AE, Alaoui-Jamali MA, Batist G, et al. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 2002;21: 2634-2640. (Pubitemid 34478321)
57. Xavier FC, Rodini CO, Ramalho LM, et al. WNT-5A, but not matrix metalloproteinase 3 or beta-catenin protein, expression is related to early stages of lip carcinogenesis. J Oral Pathol Med 2009;38:708-715.
58. Lee EH, Chari R, Lam A, et al. Disruption of the noncanonical WNT pathway in lung squamous cell carcinoma. Clin Med Oncol 2008;2008:169-179.
59. Saitoh T, Mine T, Katoh M. Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med 2002;9:515-519.
60. Saitoh T, Katoh M. Expression and regulation of WNT5A and WNT5B in human cancer: up-regulation of WNT5A by TNFalpha in MKN45 cells and upregulation of WNT5B by beta-estradiol in MCF-7 cells. Int J Mol Med 2002;10:345-349.
61. Lejeune S, Huguet EL, Hamby A, et al. Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1995;1:215-222.
62. Bachmann IM, Straume O, Puntervoll HE, et al. Importance of P-cadherin, beta-catenin, and Wnt5a/ frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 2005;11:8606-8614. (Pubitemid 43005907)
63. Da Forno PD, Pringle JH, Hutchinson P, et al. WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res 2008;14: 5825-5832.
64. Dormán G, Cseh S, Hajdú I, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010;70:949-964.
65. Folgueras AR, Pendás AM, Sánchez LM, et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004;48: 411-424. (Pubitemid 39360392)
66. Freije JM, Balb?́n M, Pendás AM, et al. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107. (Pubitemid 37176782)
67. Saleh A, Zain RB, Hussaini H, et al. Transcriptional profiling of oral squamous cell carcinoma using formalin-fixed paraffin-embedded samples. Oral Oncol 2010;46:379-386.
68. Stokes A, Joutsa J, Ala-Aho R, et al. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res 2010;16: 2022-2035.
69. Suhr ML, Dysvik B, Bruland O, et al. Gene expression profile of oral squamous cell carcinomas from Sri Lankan betel quid users. Oncol Rep 2007;18: 1061-1075.
70. Toruner GA, Ulger C, Alkan M, et al. Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet 2004;154:27-35. (Pubitemid 39286169)
71. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2004;19:6642-6650.
72. Rehman I, Tactinic keratosisata M, Wu YY, et al. Genetic change in actinic keratoses. Oncogene 1996; 12:2483-2490. (Pubitemid 26237776)